Loading...
•
Mar 31, 2022
Caribou Biosciences Q1 2022 Earnings Report
Caribou Biosciences reported financial results for the first quarter of 2022 and provided business updates.
Key Takeaways
Caribou Biosciences reported a net loss of $19.1 million for the first quarter of 2022, compared to a net loss of $13.2 million for the same period in 2021. The company's cash, cash equivalents, and marketable securities totaled $390.8 million as of March 31, 2022.
Initial ANTLER Phase 1 clinical data is scheduled to be shared at the European Hematology Association (EHA) 2022 Hybrid Congress for CB-010 in patients with r/r B-NHL.
Submission of IND application planned in H2 2022 for CB-011 for evaluation in patients with r/r multiple myeloma.
Caribou had $390.8 million in cash, cash equivalents, and marketable securities as of March 31, 2022.
Caribou expects to announce target selection for CB-020 in Q4 2022.
Caribou Biosciences
Caribou Biosciences
Caribou Biosciences Revenue by Segment
Revenue by Segment
Licensing and collaboration Revenue
CapyFin.com Forward Guidance
Caribou anticipates several milestones for 2022 and beyond, focusing on clinical data releases, IND application submissions, and target selection announcements for their allogeneic CAR-T and CAR-NK cell therapies.
Positive Outlook
- CB-010: Scheduled to share initial data from its ongoing ANTLER Phase 1 trial at EHA in June 2022.
- CB-011: Expects to submit an IND application in H2 2022.
- CB-020: Expects to announce target selection in Q4 2022.
- CB-012: Expects to submit an IND application in 2023.
- Presents poster highlighting the mechanism underlying the superior specificity of its CRISPR hybrid RNA-DNA (chRDNA) guides for genome editing of primary human T cells on May 16, 2022
Challenges Ahead
- Risks inherent in the development of cell therapy products.
- Uncertainties related to the initiation, cost, timing, progress, and results of current and future research and development programs, preclinical studies, and clinical trials.
- Risk that initial or interim clinical trial data will not be predictive of the safety and efficacy of Caribou’s product candidates.
- Clinical outcomes may differ as more patient data becomes available.
- Reliance on forward-looking statements as predictions of future events.